Moderna
-
Warminster-Founded Arbutus Biopharma to Receive $190M in Moderna Settlement
Four years after suing Moderna over its Covid-19 vaccine, Arbutus Biopharma, which was formerly headquartered in Warminster, has secured a $190 million share of a…
-
Carisma Therapeutics Selects First Drug Candidate Under Moderna Partnership, Triggers $2M Payment
Philadelphia-based Carisma Therapeutics has chosen an experimental cell therapy that targets the most prevalent type of liver cancer as the first drug development candidate under…
-
Penn Vet School, Nobel Prize Winner Dr. Drew Weissman, Collaborate On New mRNA Initiative
A new initiative has been launched at the University of Pennsylvania School of Veterinary Medicine to accelerate the development of mRNA-based vaccines and therapies for…
-
Blumberg Institute Names Former Moderna SVP as New President
The Board of Directors for Doylestown’ Blumberg Institute has named Dr. Randall N. Hyer as its new president. Hyer, a former executive with Moderna, replaces…
-
Doylestown Spinoff Leverages mRNA Tech to Address Hep B, Cancer, and Lyme Disease
Merlin Biotech of Doylestown will use its Blumberg Institute pedigree, its Pa. Biotechnology Center location, and the guidance of a former Moderna executive to get…
-
Arbutus Biopharma Corp., Warminster, Files Patent Infringement Lawsuit over COVID-19 Vaccine
Arbutus Biopharma Corp., Warminster, has filed a patent infringement lawsuit against Moderna Inc. The claim seeks unspecified damages related to Moderna’s widely distributed COVID-19 vaccine.…
Founding Partners
Advertisement
Affiliate Partners
